手机版 English 帮助中心
外文文献知网节
文献信息节点
基本信息 摘要 关键词 核心评价 相关文献
Journal | [J] 医学研究 Volume 5, Issue 24. 2023.
FoxM1在膀胱尿路上皮癌中的研究进展
作者 : 倪 璐, 宋旭 东*
DOI: 10.12361/2661-3603-05-24-154290
全部来源
获取全文
摘要 / Abstract
摘要:膀胱尿路上皮癌约占膀胱癌的90%，多数表现为典型的乳头状，是发病率和死亡率最高的肿瘤之一，也是第二常见的泌尿外科癌症。FoxM1定位于染色体带的12p13-3，长度大约为25kb，其编码基因主要是由10个外显子组成。FoxM1是一种关键的细胞周期调节因子。它控制G1/S和G2/M转换所需基因的表达；它对有丝分裂的进入和进展至关重要，确保维持染色体的稳定性。FoxM1在癌症的进展、侵袭和转移中起着重要作用，有可能被是早期诊断的潜在候选生物标志物和癌症治疗的靶点。在临床实践中，检测FoxM1蛋白表达和基因扩增可以帮助临床医生制定更有效的化疗方案，有助于判断疾病进展以及预测患者预后。本文总结FoxM1在膀胱尿路上皮癌中的表达及临床意义，以期为临床膀胱尿路上皮癌的治疗提供新的理论依据和治疗靶标。
关键词 / Keywords
关键词：FoxM1；膀胱尿路上皮癌；文献综述
Related articles / 相关文献
相似文献
作者发文
机构发文
关键词分析
相似文献（说明：与本文内容较接近的文献）
  • [1] Wang G, Mckenney J K. Urinary Bladder Pathology: World
  • Health Organization Classification and American Joint Committee on
  • Cancer Staging Update[J]. Arch Pathol Lab Med, 2019, 143(5):
  • 571-577.
  • [2] Green D A, Rink M, Xylinas E, et al. Urothelial carcinoma of
  • the bladder and the upper tract: disparate twins[J]. J Urol, 2013,
  • 189(4): 1214-21.
  • [3] 何旺, 黄海. 2022 ASCO-GU 尿路上皮癌精粹解析[J].
  • 中华泌尿外科杂志, 2022, 43(04): 245-248.
  • [4] Lu M, Hu K. Correlation of HER2 and FOXM1 in human
  • colorectal carcinoma and its clinical significance[J]. International
  • journal of clinical and experimental pathology, 2017, 10(12):
  • 11624-11634.
  • [5] Myatt S S, Lam E W. The emerging roles of forkhead box
  • (Fox) proteins in cancer[J]. Nat Rev Cancer, 2007, 7(11): 847-59.
  • [6] Hegde N S, Sanders D A, Rodriguez R, et al. The
  • transcription factor FOXM1 is a cellular target of the natural product
  • thiostrepton[J]. Nat Chem, 2011, 3(9): 725-31.
  • [7] Ye H, Kelly T F, Samadani U, et al. Hepatocyte nuclear
  • factor 3/fork head homolog 11 is expressed in proliferating epithelial
  • and mesenchymal cells of embryonic and adult tissues[J]. Molecular
  • and Cellular Biology, 1997, 17(3): 1626-1641.
  • [8] Borhani S, Gartel A L. FOXM1: a potential therapeutic target
  • in human solid cancers[J]. Expert Opin Ther Targets, 2020, 24(3):
  • 205-217.
  • [9] Nakamura S, Hirano I, Okinaka K, et al. The FOXM1
  • transcriptional factor promotes the proliferation of leukemia cells
  • through modulation of cell cycle progression in acute myeloid
  • leukemia[J]. Carcinogenesis, 2010, 31(11): 2012-21.
  • [10] Liu D, Zhang Z, Kong C Z. High FOXM1 expression was
  • associated with bladder carcinogenesis[J]. Tumour Biol, 2013, 34(2):
  • 1131-8.
  • [11] Fu M, Chen H, Cai Z, et al. Forkhead box family
  • transcription factors as versatile regulators for cellular
  • reprogramming to pluripotency[J]. Cell Regen, 2021, 10(1): 17.
  • [12] Koo C Y, Muir K W, Lam E W. FOXM1: From cancer
  • initiation to progression and treatment[J]. Biochim Biophys Acta,
  • 2012, 1819(1): 28-37.
  • [13] Chen Y, Wang B C, Xiao Y. PI3K: A potential therapeutic
  • target for cancer[J]. Journal of Cellular Physiology, 2012, 227(7):
  • 2818-2821.
  • [14] Wang Z, Banerjee S, Kong D, et al. Down-regulation of
  • Forkhead Box M1 transcription factor leads to the inhibition of
  • invasion and angiogenesis of pancreatic cancer cells[J]. Cancer Res,
  • 2007, 67(17): 8293-300.
  • [15] Yoshida Y, Wang I C, Yoder H M, et al. The forkhead box
  • M1 transcription factor contributes to the development and growth of
  • mouse colorectal cancer[J]. Gastroenterology, 2007, 132(4):1420-31.
  • [16] Balli D, Zhang Y, Snyder J, et al. Endothelial
  • Cell–Specific Deletion of Transcription Factor FoxM1 Increases
  • Urethane-Induced Lung Carcinogenesis[J]. Cancer Research, 2011,
  • 71(1): 40-50.
  • [17] Kalin, T. V. Increased Levels of the FoxM1 Transcription
  • Factor Accelerate Development and Progression of Prostate
  • Carcinomas in both TRAMP and LADY Transgenic Mice[J]. Cancer
  • Research, 2006, 66(3): 1712.
  • [18] Wang I C, Meliton L, Tretiakova M, et al. Transgenic
  • expression of the forkhead box M1 transcription factor induces
  • formation of lung tumors[J]. Oncogene, 2008, 27(30): 4137-49.
  • [19] Nilsson J, Helou K, Kovacs A, et al. Nuclear
  • Janus-activated kinase 2/nuclear factor 1-C2 suppresses
  • tumorigenesis and epithelial-to-mesenchymal transition by
  • repressing Forkhead box F1[J]. Cancer Res, 2010, 70(5): 2020-9.
  • [20] Frau M, Biasi F, Feo F, et al. Prognostic markers and
  • putative therapeutic targets for hepatocellular carcinoma[J]. Mol
  • Aspects Med, 2010, 31(2): 179-93.
  • [21] Chu X Y, Zhu Z M, Chen L B, et al. FOXM1 expression
  • correlates with tumor invasion and a poor prognosis of colorectal
  • cancer[J]. Acta Histochem, 2012, 114(8): 755-62.
  • [22] Seyedabadi S, Saidijam M, Najafi R, et al. Assessment of
  • CEP55, PLK1 and FOXM1 expression in patients with bladder
  • cancer in comparison with healthy individuals[J]. Cancer Invest,
  • 2018, 36(8): 407-414.
  • [23] Uddin S, Ahmed M, Hussain A, et al. Genome-wide
  • expression analysis of Middle Eastern colorectal cancer reveals
  • FOXM1 as a novel target for cancer therapy[J]. American Journal of
  • Pathology, 2011, 178(2): 537-547.
  • [24] Priller M, Poschl J, Abrao L, et al. Expression of FoxM1 is
  • required for the proliferation of medulloblastoma cells and indicates
  • worse survival of patients[J]. Clinical Cancer Research An Official
  • Journal of the American Association for Cancer Research, 2011,
  • 17(21): 6791-801.
  • [25] Yun-Yong P, Yun J S, Jennings N B, et al. FOXM1
  • mediates Dox resistance in breast cancer by enhancing DNA repair[J].
  • Carcinogenesis, 2012, 33(10): 10.
  • [26] Ueno H, Nakajo N, Watanabe M, et al. FoxM1-driven cell
  • division is required for neuronal differentiation in early Xenopus
  • embryos[J]. Development, 2008, 135(11): 2023-30.
  • [27] Kuda M, Kohashi K, Yamada Y, et al. FOXM1 expression
  • in rhabdomyosarcoma: a novel prognostic factor and therapeutic
  • target[J]. Tumor Biology, 2016, 37(4): 5213-5223.
  • [28] Wen N, Wang Y, Wen L, et al. Overexpression of FOXM1
  • predicts poor prognosis and promotes cancer cell proliferation,
  • migration and invasion in epithelial ovarian cancer[J]. Journal of
  • Translational Medicine, 2014, 12(1): 134-147.
  • [29] Yi L, Wang H, Li W, et al. The FOXM1/RNF26/p57 axis
  • regulates the cell cycle to promote the aggressiveness of bladder
  • cancer[J]. Cell Death Dis, 2021, 12(10): 944-956.
  • [30] Rinaldetti S, Wirtz R M, Worst T S, et al. FOXM1 predicts
  • overall and disease specific survival in muscle-invasive urothelial
  • carcinoma and presents a differential expression between bladder
  • cancer subtypes[J]. Oncotarget, 2017, 8(29): 47595-47606.
  • [31] 曹煜东, 杜鹏. 肌层浸润性膀胱癌分子分型的研究进
  • 展[J]. 中华泌尿外科杂志, 2019, 40(6): 477-480.
  • [32] Wulfing C, Machiels J P, Richel D J, et al. A single-arm,
  • multicenter, open-label phase 2 study of lapatinib as the second-line
  • treatment of patients with locally advanced or metastatic transitional
  • cell carcinoma[J]. Cancer, 2009, 115(13): 2881-90.
  • [33] Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in
  • metastatic urothelial carcinoma after platinum therapy (CheckMate
  • 275): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2017,
  • 18(3): 312-322.
  • [34] Babjuk M, Oosterlinck W, Sylvester R, et al. EAU
  • guidelines on non-muscle-invasive urothelial carcinoma of the
  • bladder[J]. Eur Urol, 2008, 54(2): 303-14.
  • [35] Sharma P, Callahan M K, Bono P, et al. Nivolumab
  • monotherapy in recurrent metastatic urothelial carcinoma
  • (CheckMate 032): a multicentre, open-label, two-stage, multi-arm,
  • phase 1/2 trial[J]. Lancet Oncol, 2016, 17(11): 1590-1598.
  • [36] Choi W, Porten S, Kim S, et al. Identification of distinct
  • basal and luminal subtypes of muscle-invasive bladder cancer with
  • different sensitivities to frontline chemotherapy[J]. Cancer Cell, 2014,
  • 25(2): 152-165.
  • [37] Hedegaard J, Lamy P, Nordentoft I, et al. Comprehensive
  • Transcriptional Analysis of Early-Stage Urothelial Carcinoma[J].
  • Cancer Cell, 2016, 30(1): 27-42.
《中国学术期刊(光盘版)》电子杂志社有限公司 KDN平台基础技术由KBASE 11.0提供
© 2014-2018中国知网(CNKI) 京公网安备11010802020460号 经营性网站备案信息 互联网出版许可证 新出网证(京)字271号 京ICP证040431号